Industry News

Pharmaceutical Industry News

In the letters sent to 30…

March 3rd, 2026|Fierce Pharma|

In the letters sent to 30 different telehealth companies that market compounded versions of GLP-1 drugs, the agency threatened "legal action without further notice."

Pfizer CEO Albert Bourla, Ph.D.,…

March 3rd, 2026|Fierce Pharma|

Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp criticism of the FDA’s Vinay Prasad, M.D., and his performance as the chief of the Center for Biologics Evaluation and Research, which regulates vaccines in

Amid an influx of U.S….

March 3rd, 2026|Fierce Pharma|

Amid an influx of U.S. investments, geopolitical uncertainties support the need for manufacturing projects in other regions, IDA Ireland's Rory Mullen told Fierce.

Dr. McDreamy has signed onto yet…

March 3rd, 2026|Fierce Pharma|

Dr. McDreamy has signed onto yet another cancer awareness initiative. “Grey’s Anatomy” star Patrick Dempsey, who has worked with Amgen since 2007 and joined forces with Pfizer in 2024, is now collaborating with cancer test

The FDA is providing more insight…

March 3rd, 2026|Fierce Pharma|

The FDA is providing more insight into the rejections it recently handed two pharma giants, publishing the complete response letters (CRLs) sent to AstraZeneca and GSK that highlight shortfalls in the data included in their

Novo will invest 432 million euros…

March 3rd, 2026|Fierce Pharma|

Novo will invest 432 million euros ($501 million) to add a new tableting plant at its facility in Athlone, Ireland, the company said in a March 2 press release. The expansion will equip the Athlone

Esperion has acquired Corstasis…

March 3rd, 2026|Fierce Pharma|

Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago. Esperion paid $75 million upfront and earmarked $180 million for potential milestones while agreeing to pay

As it ramps up its rollout of the…

March 2nd, 2026|Fierce Pharma|

As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.

Since GLP-1 blockbusters…

March 2nd, 2026|Fierce Pharma|

Since GLP-1 blockbusters semaglutide and tirzepatide broke into the mainstream for their ability to treat diabetes and provoke weight loss, evidence has been piling up that the molecules can reduce the risk of heart problems

As the effects of the United…

March 2nd, 2026|Fierce Pharma|

As the effects of the United States and Israel’s weekend attack on Iran begin to ripple through the Middle East, multiple drugmakers operating in the region are taking stock of their local workforces’ safety and

The newest additions to the CDC’s…

March 2nd, 2026|Fierce Pharma|

The newest additions to the CDC's vaccine advisory committee are Florida internal medicine and pediatrics specialist Sean G. Downing, M.D., and pediatrician Angelina Farella, M.D.

With some 12 years as CEO under…

March 2nd, 2026|Fierce Pharma|

With some 12 years as CEO under his belt, Bavarian Nordic’s Paul Chaplin is telegraphing his exit from the Denmark-based vaccine maker. The planned move comes shortly after another high-profile exit at the company, with

Ascendis Pharma is spiraling…

March 2nd, 2026|Fierce Pharma|

Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based biopharma has scored an FDA approval for a rare disease medicine that was developed with

Quotient Sciences, a CDMO that…

March 2nd, 2026|Fierce Pharma|

Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs, has extended a deal with Ipsen to manufacture Sohonos (palovarotene) capsules. Sohonos is currently the only medication approved by the FDA to treat

Several Big Pharmas have…

February 27th, 2026|Fierce Pharma|

Several Big Pharmas have introduced their own podcasts to advance corporate branding efforts, while health-focused nonprofits have found in podcasts an effective awareness-raising tool with a relatively low barrier of entry in terms of production

In a Worker Adjustment and…

February 27th, 2026|Fierce Pharma|

In a Worker Adjustment and Retraining Notification Act alert filed this week, Merck revealed that it is laying off 147 staffers at a vaccine manufacturing plant in Durham. The cuts are a result of Merck's